{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00024860", "CSN": null, "TRF": "ORD_1506062_01", "MRN": "31701163", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1227277", "clinicalId": "1228647", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1506062_01", "SampleName": "US1441945.02", "Version": "0", "Sample": {"FM_Id": "ORD_1506062_01", "SampleId": "US1441945.02", "BlockId": "S111-44771A+B", "TRFNumber": "ORD_1506062_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_11_17", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "30", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M111-10019", "MRN": "31701163", "FullName": "\u8a31\u4fe1\u4e00", "FirstName": "Hsin Yi", "LastName": "Hsu", "SubmittedDiagnosis": "Metastatic carcinoma", "Gender": "Male", "DOB": "1942_08_14", "OrderingMD": "\u5289\u5cfb\u5b87", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Lung", "CollDate": "2022_11_01", "ReceivedDate": "2022-11-30 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Carcinoma, NOS"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "15", "clinicalTrialCount": "23", "resistiveCount": "0", "sensitizingCount": "3"}, "VariantProperties": {"VariantProperty": [{"geneName": "BRCA1", "isVUS": "true", "variantName": "P346S"}, {"geneName": "CASP8", "isVUS": "true", "variantName": "Q46H"}, {"geneName": "CDH1", "isVUS": "true", "variantName": "L21V"}, {"geneName": "CREBBP", "isVUS": "true", "variantName": "M1691L"}, {"geneName": "GATA6", "isVUS": "true", "variantName": "A179_A183del"}, {"geneName": "NBN", "isVUS": "true", "variantName": "amplification"}, {"geneName": "NTRK2", "isVUS": "true", "variantName": "G195V"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "HRAS", "Include": "true", "Alterations": {"Alteration": {"Name": "Q61R", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Q61R"}}, "Interpretation": "HRAS encodes a member of the RAS family of membrane proteins that bind GDP/GTP and possess GTPase activity. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation (Pylayeva_Gupta et al., 2011; 21993244). HRAS alterations affecting amino acids G12, G13, Q61 and K117, as well as the mutations A59T, A146T, A146V, and in_frame duplications in the HRAS switch II region, have been characterized to be activating and oncogenic (Baker et al., 2013; 24247240, Buhrman et al., 2010; 20194776, Denayer et al., 2008; 17979197, Fasano et al., 1984; 6330729, Feig et al., 1988; 3043178, Janakiraman et al., 2010; 20570890, Prive et al., 1992; 1565661, Pylayeva_Gupta et al., 2011; 21993244, Scheffzek et al., 1997; 9219684, Stephen et al., 2014; 24651010, Niihori et al., 2011; 21850009, Wey et al., 2013; 24224811, Eijkelenboom et al., 2019; 31160609, Lorenz et al., 2013; 23335589). HRAS mutation has been implicated in salivary gland tumorigenesis and reported in adenocarcinomas as well as other histological subtypes of salivary gland carcinoma (Elledge, 2009; 19317835, Vander et al., 2012; 21618326, Milasin et al., 1993; 8106812, Deguchi et al., 1993; 8396843, van Halteren et al., 1994; 8168996, Yoo and Robinson, 2000; 10649241, Yoo and Robinson, 2000; 10835516, Cros et al., 2013; 23933559). In salivary gland adenocarcinomas, HRAS mutations have been reported in 3/13 cases (23%) examined in one study, but in none of nine cases in another (van Halteren et al., 1994; 8168996, Yoo and Robinson, 2000; 10835516). In one study of salivary gland adenocarcinomas, no statistically significant differences in recurrence or overall survival were detected regardless of HRAS mutational status (van Halteren et al., 1994; 8168996). On the basis of significant clinical benefit for 1 patient each with cholangiocarcinoma (Nadauld et al., 2016; ASCO Abstract e23162) and salivary gland carcinoma (Chintakuntlawar et al., 2015; ASCO Abstract e17053) treated with trametinib, as well as strong preclinical data (Rosenberger et al., 2009; 19035362, Rosseland et al., 2008; 18163378, Ricciardi et al., 2012; 22399013, Leiser et al., 2015; 25933688, Kiessling et al., 2015; 26544513), HRAS activating alterations may predict sensitivity to MEK inhibitors, such as binimetinib, cobimetinib, trametinib, and selumetinib. The reovirus Reolysin targets cells with activated RAS signaling (Strong et al., 1998; 9628872, Coffey et al., 1998; 9812900, Gong and Mita, 2014; 25019061) and has demonstrated mixed clinical efficacy, with the highest rate of response reported for head and neck cancer (Forsyth et al., 2008; 18253152, Vidal et al., 2008; 18981012, Gollamudi et al., 2010; 19572105, Harrington et al., 2010; 20484020, Comins et al., 2010; 20926400, Lolkema et al., 2011; 21106728, Galanis et al., 2012; 22871663, Karapanagiotou et al., 2012; 22316603, Morris et al., 2013; 22886613). HRAS activating mutations may also predict sensitivity to farnesyl transferase inhibitors based on Phase 2 studies of tipifarnib in head and neck squamous cell carcinoma (HNSCC) with HRAS_mutated allele frequency \u226520% (ORR of 50.0% [9/18], mDOR of 14.7 months, mPFS of 5.9 months, and mOS of 15.4 months), HRAS_mutated salivary gland cancer (8.3% [1/12] PRs, 58.3% [7/12] SDs, mPFS of 7.0 months), and HRAS_mutated metastatic urothelial carcinoma (ORR of 41.7% [5/12], mPFS of 5.1 months) (Ho et al., 2020; ASCO Abstract 6504), as well as preclinical evidence in various cancer types (End et al., 2001; 11196150, Chen et al., 2014; 24240680, Cohen_Jonathan et al., 2000; 10931682). HRAS mutations have been associated with secondary tumors, particularly cutaneous SCCs, occurring after treatment of primary tumors with RAF inhibitors (Oberholzer et al., 2012; 22067401, Su et al., 2012; 22256804, Lacouture et al., 2013; 23457002). Preclinical studies have also reported that activating HRAS mutations are associated with resistance to EGFR inhibitors (Hah et al., 2013; 24123531, Frasca et al., 2013; 23559083, Kasper et al., 2013; 22797062).", "Include": "true", "ClinicalTrialNote": "HRAS activating alterations may predict sensitivity to MEK or farnesyl transferase inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Cobimetinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Cobimetinib is a MEK inhibitor that is FDA approved to treat patients with histiocytic neoplasms. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of limited clinical data (Nadauld et al., 2016; ASCO Abstract e23162, Chintakuntlawar et al., 2015; ASCO Abstract e17053) and strong preclinical data (Rosenberger et al., 2009; 19035362, Rosseland et al., 2008; 18163378, Ricciardi et al., 2012; 22399013, Leiser et al., 2015; 25933688, Kiessling et al., 2015; 26544513), HRAS activating alterations may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of cobimetinib for the treatment of salivary gland carcinoma are limited (PubMed, Nov 2022). Single_agent cobimetinib has shown clinical activity in the context of histiocytic neoplasms, including Langerhans cell histiocytosis, Erdheim_Chester disease, Rosai_Dorfman disease, nodular histiocytosis, and mixed histiocytosis (Diamond et al., 2015; 26566875, Diamond et al., 2019; 30867592, Jacobsen et al., 2019; 29236635, Berce et al., 2022; 35372654, Giuffre et al., 2020; 32823478, Razanamahery et al., 2020; 31376269, Moyon et al., 2020; 31669429, Gupta et al., 2022; 36135991). A Phase 1 study of cobimetinib monotherapy in solid tumors reported CRs for 1.0% (1/97) of patients and PRs for 6.2% (6/97) of patients, all of whom had melanoma (Rosen et al., 2016; 27424159). Clinical benefit following treatment with cobimetinib has been seen for patients with non_small cell lung cancer (NSCLC) (Cho et al., 2020; AACR Abstract CT201, Rosen et al., 2016; 27424159), adenoid cystic carcinoma (Rosen et al., 2016; 27424159), and anaplastic pleomorphic xanthoastrocytoma (Touat et al., 2019; DOI: 10.1200/PO.18.00298). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Selumetinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Selumetinib is a MEK inhibitor that is FDA approved to treat pediatric patients with neurofibromatosis type 1 (NF1)_associated plexiform neurofibromas (PNs). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of limited clinical data (Nadauld et al., 2016; ASCO Abstract e23162, Chintakuntlawar et al., 2015; ASCO Abstract e17053) and strong preclinical data (Rosenberger et al., 2009; 19035362, Rosseland et al., 2008; 18163378, Ricciardi et al., 2012; 22399013, Leiser et al., 2015; 25933688, Kiessling et al., 2015; 26544513), HRAS activating alterations may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of selumetinib for the treatment of salivary gland and mucoepidermoid carcinoma are limited (PubMed, Nov 2022). Selumetinib has demonstrated efficacy in NF1_associated neurofibroma in Phase 2 studies (Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612) and a Phase 1 study (Dombi et al., 2016; 28029918). Phase 2 studies reported clinical responses in low_grade glioma (Fangusaro et al., 2019; 31151904, Banerjee et al., 2017; 28339824), melanoma (Gupta et al., 2014; 24567366, Robert et al., 2013; 23735514, Kirkwood et al., 2012; 22048237, Banerji et al., 2010; 20179232, Boers_Sonderen et al., 2012; 22293660), and in lung (Lopez_Chavez et al., 2015; 25667274, Hainsworth et al., 2010; 20802351, Middleton et al., 2020; 32669708) and endometrial cancer (Coleman et al., 2015; 25887099). A Phase 2 study of selumetinib for patients with activating alterations in the MAPK pathway reported a DCR of 15% (3/20), with no objective responses observed (Eckstein et al., 2022; 35363510). Phase 1 studies of selumetinib to treat patients with solid tumors reported 1/15 PR for a patient with colorectal cancer (CRC) and 5/15 SDs for patients with tonsil squamous cell carcinoma (SCC), non_small cell lung cancer (NSCLC), and CRC (Deming et al., 2016; 26666244); 2/39 PRs (for patients with CRC) and 18/39 SDs were achieved when selumetinib was administered in combination with cyclosporin A (Krishnamurthy et al., 2018; 30042150). Multiple Phase 1 studies combining selumetinib with erlotinib or temsirolimus (Infante et al., 2017; 28424891), docetaxel or dacarbazine (LoRusso et al., 2017; 28264648), AKT inhibitors (Tolcher et al., 2015; 25516890), or cixutumumab (an anti_IGF_1R antibody)(Wilky et al., 2015; 25268371) reported clinical responses for patients with advanced solid tumors including NSCLC, thyroid carcinoma, tongue SCC, and ovarian cancer. </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Trametinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Trametinib is a MEK inhibitor that is FDA approved as a monotherapy to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of limited clinical data (Nadauld et al., 2016; ASCO Abstract e23162, Chintakuntlawar et al., 2015; ASCO Abstract e17053) and strong preclinical data (Rosenberger et al., 2009; 19035362, Rosseland et al., 2008; 18163378, Ricciardi et al., 2012; 22399013, Leiser et al., 2015; 25933688, Kiessling et al., 2015; 26544513), HRAS activating alterations may predict sensitivity to MEK inhibitors. </p> <p><b>Supporting Data:</b> A Phase 1 trial of trametinib in 206 patients with solid tumors reported 21 (10%) objective responses (Infante et al., 2012; 22805291). Phase 1 monotherapy trials of RO4987655, another MEK inhibitor, have shown significant response rates in patients with melanoma, including those with BRAF and NRAS mutations, but very low response rates in patients with other solid tumors, including those with KRAS mutations (Leijen et al., 2012; 22767668, Zimmer et al., 2014; 24947927). A Phase 1b trial of trametinib in combination with gemcitabine in patients with solid tumors showed a complete response in a patient with breast cancer, as well as partial responses in pancreatic and salivary gland cancer (Infante et al., 2013; 23583440). A Phase 1b trial of combination treatment with the MEK inhibitor binimetinib and the PI3K_alpha inhibitor alpelisib reported disease control (partial responses or stable disease) in 47% (21/45) of patients, including partial responses in 2 of 3 patients with KRAS_mutant ovarian cancer and 1 of 3 patients with NRAS_mutant melanoma; a 43% rate of stable disease was observed in patients with KRAS_mutant colorectal cancer, with responses independent of PIK3CA mutation status (Juric et al., 2014; ASCO Abstract 9051). In Phase 1b trials of trametinib as a single agent or in combination with gemcitabine, 2 PRs were reported for patients with salivary gland cancer (Infante et al., 2013; 23583440, Kurata et al., 2013; ASCO Abstract e20004). A patient with HRAS Q61R_positive epithelial_myoepithelial salivary gland carcinoma experienced a PR for 5 months to treatment with trametinib (Chintakuntlawar et al., 2015; ASCO Abstract e17053). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04985604", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03284502", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04720976", "Include": "true"}, {"nctId": "NCT04965818", "Include": "true"}, {"nctId": "NCT03905148", "Include": "true"}, {"nctId": "NCT05159245", "Include": "true"}, {"nctId": "NCT04551521", "Include": "true"}, {"nctId": "NCT04892017", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "MYC", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "MYC (c_MYC) encodes a transcription factor that regulates many genes related to cell cycle regulation and cell growth. It is an oncogene and may be activated in as many as 20% of cancers (Dang et al., 2006; 16904903). MYC dysregulation (amplification, overexpression, translocation) has been identified in a number of different cancer types (Nesbit et al., 1999; 10378696). MYC amplification has been significantly linked with increased mRNA and protein levels and results in the dysregulation of a large number of target genes (Blancato et al., 2004; 15083194, Dang et al., 2006; 16904903, Fromont et al., 2013; 23574779). MYC amplification has been reported in various solid tumors including breast (9.6%), ovarian (6.7%), melanoma (5.8%), endometrial (5.5%), non_small cell lung (5.5%), prostate (4.7%), esophagogastric (4.4%), and colorectal (3.9%) cancer (cBio_Zehir et al., 2017; 28481359). An early study reported MYC protein expression in 42% of salivary gland pleomorphic adenomas and 56% of carcinomas in pleomorphic adenoma of the salivary gland (Deguchi et al., 1993; 8396843). MYC protein expression has also been detected in 86% (12/14) of adenoid cystic carcinomas in one study (von Holstein et al., 2013; 23725736). Published data investigating the prognostic implications of MYC alterations in salivary gland carcinomas are limited (PubMed, Oct 2022). In 1 study, MYC overexpression was associated with fusions in MYB and shorter disease_free survival for patients with salivary gland ACC (n=33) (Fujii et al., 2017; 28594149). Preclinical data indicate MYC overexpression may predict sensitivity to investigational agents targeting CDK1 (Horiuchi et al., 2012; 22430491, Goga et al., 2007; 17589519), CDK2 (Molenaar et al., 2009; 19525400), Aurora kinase A (Dammert et al., 2019; 31375684, Mollaoglu et al., 2017; 28089889, Robert et al., 2017; 29088717, Wang et al., 2017; 28417568, Takahashi et al., 2015; 25632068, Li et al., 2018; 30226440, Kong et al., 2017; DOI: 10.21037/tcr.2017.06.41, Mahadeva et al., 2014; 24893165, Park et al., 2019; 31429028), Aurora kinase B (Helfrich et al., 2016; 27496133, Hook et al., 2012; 22222631, Yang et al., 2010; 20643922, He et al., 2019; 30540594), glutaminase (Shroff et al., 2015; 25964345, Effenberger et al., 2017; 29156762, Shen et al., 2018; 30103944, Xiang et al., 2015; 25915584), or BET bromodomain_containing proteins (Delmore et al., 2011; 21889194, Bandopadhayay et al., 2013; 24297863, Loven et al., 2013; 23582323, Otto et al., 2019; 31734632), as well as agents targeting both HDAC and PI3K (Dong et al., 2013; 23866964, Pei et al., 2016; 26977882; Fu et al., 2019; 30224636). Exploratory biomarker analysis in a Phase 2 study reported a PFS benefit associated with a combination of the Aurora A kinase inhibitor alisertib and paclitaxel as second_line therapy for patients with MYC_overexpressed small cell lung cancer but not for patients without MYC overexpression (Owonikoko et al., 2020; 31655296). A PR was reported for a patient with MYC_amplified invasive ductal breast carcinoma treated with an unspecified Aurora kinase inhibitor and taxol (Ganesan et al., 2014; 25253784). MYC amplification has also been suggested to predict response to chemotherapy in patients with breast cancer in some studies (Pereira et al., 2013; 23555992, Yasojima et al., 2011; 21741827). Preclinical evidence suggests that colon cancer cells with MYC amplification may be more sensitive to 5_fluorouracil and paclitaxel (Arango et al., 2001; 11406570, Bottone et al., 2003; 14516787).", "Include": "true", "ClinicalTrialNote": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04983810", "Include": "true"}, {"nctId": "NCT05252390", "Include": "true"}, {"nctId": "NCT04742959", "Include": "true"}, {"nctId": "NCT04840589", "Include": "true"}, {"nctId": "NCT04555837", "Include": "true"}, {"nctId": "NCT01434316", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PIK3CA", "Include": "true", "Alterations": {"Alteration": {"Name": "E545K, P539R", "AlterationProperties": {"AlterationProperty": [{"isEquivocal": "false", "name": "E545K"}, {"isEquivocal": "false", "name": "P539R"}]}, "Interpretation": "PIK3CA encodes p110_alpha, which is the catalytic subunit of phosphatidylinositol 3_kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival (Samuels et al., 2005; 15950905, Engelman, 2009; 19629070). PIK3CA alterations that have been characterized as activating, such as observed here, are predicted to be oncogenic (Kang et al., 2005; 15647370, Ikenoue et al., 2005; 15930273, Gymnopoulos et al., 2007; 17376864, Horn et al., 2008; 18317450, Rudd et al., 2011; 21266528, Hon et al., 2012; 22120714, Burke et al., 2012; 22949682, Wu et al., 2009; 19915146, Dbouk et al., 2010; 2103068, Dan et al., 2010; 20530683, Oda et al., 2008; 18829572, Zhao and Vogt, 2008; 18794883, Lui et al., 2013; 23619167, Ross et al., 2013; 22430209, Riviere et al., 2012; 22729224, Shibata et al., 2009; 19394761, Droguluk et al., 2015; 26627007, Croessmann et al., 2018; 29284706, Ng et al., 2018; 29533785, Spangle et al., 2020; 32929011, Chen et al., 2018; 29636477, Jin et al., 2021; 34779417). PIK3CA mutations have been reported in various malignancies, with the highest incidences in carcinomas of the uterus (51%)(Cancer Genome Atlas Research Network, 2013; 23636398), breast (36%)(cBio_Stephens et al., 2012; 22722201, cBio_Banerji et al., 2012; 22722202, Cancer Genome Atlas Network, 2012; 23000897), bladder (23%)(Cancer Genome Atlas Research Network, 2014; 24476821, cBio_Guo et al., 2013; 24121792, cBio_Iyer et al., 2013; 23897969, cBio_Kim et al., 2014; 25092538), head and neck (15%)(HNSCC_Cancer Genome Atlas Network, 2015; 25631445), and stomach (18%)(Cancer Genome Atlas Research Network, 2014; 25079317). Published data investigating the prognostic implications of PIK3CA alterations in salivary gland carcinomas are limited (PubMed, Nov 2022). Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K (Fritsch et al., 2014; 24608574, Juric et al., 2018; 29401002, Gallant et al., 2019; 30793038, Canaud et al., 2021; ESMO Abstract LBA23, Delestre et al., 2021; 34613809, Morschhauser et al., 2020; 31619463, Patnaik et al., 2016; 27672108, Santin et al., 2020; 31934607, Damodaran et al., 2022; 35133871), AKT (Andre et al., 2019; 31091374, Smyth et al., 2021; 33863913), or mTOR (Varnier et al., 2019; 31351267, Basse et al., 2018; 32914004, Sultova et al., 2021; 33277683, Mackay et al., 2014; 24166148, Myers et al., 2016; 27016228, Dhami et al., 2018; 29588307, Harris et al., 2019; 30863722, Hanna et al., 2018; 29301825). The Phase 2 NCI_MATCH study of copanlisib for patients with refractory solid tumors harboring PIK3CA mutations with or without PTEN loss met its primary endpoint with an ORR of 16% (4/25 PRs); responses (PR or SD >6 months) were seen in patients with ameloblastoma, liposarcoma, and carcinomas of the endometrium, ovary, esophagus, lung, and prostate (Damodaran et al., 2022; 35133871). However, the Phase 2 study of copanlisib for patients with endometrial carcinoma harboring PIK3CA hotspot mutations failed to report any objective responses (n=11)(Santin et al., 2020; 31934607). Two other studies of copanlisib for patients with genomically unselected tumors reported 1 CR and 2 PRs (1 unconfirmed) among 16 total patients with PIK3CA_mutated solid tumors with or without PTEN alterations (Morschhauser et al., 2020; 31619463, Patnaik et al., 2016; 27672108). In the Phase 2 MATCH trial for patients with PIK3CA_mutated solid tumors, 28% (18/65) of patients experienced PFS lasting at least 6 months after treatment with taselisib; however, no ORs were observed in this study (Krop et al., 2018; ASCO Abstract 101). A separate Phase 1b study of taselisib in combination with the CDK4/6 inhibitor palbociclib for patients with PIK3CA_mutated solid tumors reported an ORR of 0% (n=12) and a DCR of 17% (2/12) (Pascual et al., 2021; 32958578). In a Phase 1 trial of the dual PI3K/mTOR kinase inhibitor apitolisib, 79% (11/14) of patients with PIK3CA_mutated advanced solid tumors experienced disease control (3 PRs, 8 SDs) (Dolly et al., 2016; 26787751). The PI3K inhibitor alpelisib is approved as a single agent for the treatment of patients with PIK3CA_related overgrowth spectrum (PROS) (Canaud et al., 2021; ESMO Abstract LBA23), but has shown limited activity as monotherapy for PIK3CA_mutated solid tumors with a Phase 1a study reporting an ORR of 6.0% (8/134) and a DCR of 58% (78/134) (Juric et al., 2018; 2941002).", "Include": "true", "ClinicalTrialNote": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04589845", "Include": "true"}, {"nctId": "NCT04341259", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT04526470", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT04551521", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}, {"nctId": "NCT03006172", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "LYN", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "LYN encodes a SRC family intracellular membrane_associated tyrosine protein kinase. LYN is expressed predominantly in hematopoietic cells and conveys signals from the B_cell receptor (BCR) and other receptors to activate the PI3K, STAT, and other signaling pathways (reviewed in Xu et al., 2005; 15664155, Ingley, 2012; 22805580). LYN alterations are rare in solid tumors (cBio_Zehir et al., 2017; 28481359, cBio_Nguyen et al., 2022; 35120664). However, LYN amplification has been reported more frequently, including in ovarian (3.1%), melanoma (2.3%), prostate (2.2%), breast (1.9%), and endometrial (1.6%) cancers (cBio_Zehir et al., 2017; 28481359, cBio_Nguyen et al., 2022; 35120664). LYN expression and activation have also been reported in several types of solid tumors, including glioblastoma (Stettner et al., 2005; 15994925), prostate cancer (Goldenberg_Furmanov et al., 2004; 14871838), head and neck squamous cell carcinoma (HNSCC)(Wheeler et al., 2012; 22490227), Ewing sarcoma (Guan et al., 2008; 18644993), and breast cancer (Choi et al., 2010; 20215510). High LYN expression was associated with lower survival rates for patients with breast, colorectal, and renal cancers (Choi et al., 2010; 20215510, Huang et al., 2013; 23764002, Su et al. 2012; 22731636, Roseweir et al., 2016; 26984511). Dasatinib is a kinase inhibitor that targets the BCR_ABL fusion protein, SRC family kinases including LYN (specifically at low nanomolar concentration)(Nam et al., 2005; 16230377, Williams et al., 2009; 18984583), and other kinases, and has been approved to treat chronic myelocytic leukemia (CML) and acute lymphoblastic leukemia (ALL). A pediatric patient with relapsed B_cell acute lymphoblastic leukemia and an NCOR1_LYN fusion achieved complete remission after 2 weeks of treatment with dasatinib (Dai et al., 2020; 32266142). Similarly, a preclinical study showed that treatment with dasatinib significantly increased survival in a xenograft model of leukemic blast cells harboring NCOR1_LYN (Tomii et al., 2021; 33199837). In preclinical studies of LYN_expressing breast and prostate cancer, dasatinib has been reported to inhibit cell migration and invasion (Choi et al., 2010; 20215510, Nam et al., 2005; 16230377). However, amplification or other genomic alterations in LYN in solid tumors, and their potential predictive value for sensitivity of these tumors to dasatinib and other kinase inhibitors, remains poorly understood.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). Rare instances of MSI have been reported in salivary gland carcinomas (Suzuki and Fujioka, 1998; 9917133, Moore et al., 2020; 31762146); however, two larger studies reported no MSI in 58 total salivary gland tumors (Ohki et al., 2001; 11829237, Nakano, 2019; 30846173). Published data investigating the prognostic implications of MSI in salivary gland carcinoma are limited (PubMed, Feb 2022). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "RAD21", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "RAD21 encodes a protein involved in DNA double_strand break repair and sister chromatid cohesion as a part of the cohesin complex (Xu et al., 2011; 21326324, Hill et al., 2016; 27207471, Solomon et al., 2014; 24856830, Bauerschmidt et al., 2010; 19906707). In preclinical studies, downregulation of RAD21 or other cohesin components leads to loss of expression from amplified genes, as well as amplifications themselves upon cell passaging (Yun et al., 2016; 26420833), but also leads to an increase in deletions, insertions, and other rearrangements (Gelot et al., 2016; 27326661). High RAD21 expression has also been associated with increased genomic instability (Yan et al., 2012; 22537934). Cohesin complex also organizes chromatin domains and regulates gene expression (Sofueva et al., 2013; 24185899, Deng et al., 2012; 23010778). Both overexpression and reduction of expression of RAD21 has been reported to alter gene expression (Yun et al., 2016; 27466323). RAD21 amplification has been correlated with increased expression in breast (Yan et al., 2012; 22537934, Xu et al., 2011; 21255398, Mahmood et al., 2014; 24148822) and endometrial (Supernat et al., 2012; 23205091) cancers. Other RAD21 alterations, including truncating and point mutations, have been reported in the context of cancer, but the majority have not been characterized. RAD21 amplifications have been reported in solid tumors, including breast cancers (7%), melanoma (5.4%), and prostate (2.4%) cancers (cBio_Zehir et al., 2017; 28481359). RAD21 overexpression has been correlated with poor prognosis in endometrial cancer (Supernat et al., 2012; 23205091), breast cancer (Xu et al., 2011; 21255398, Sharaf et al., 2022; 35227290), Ewing sarcoma (Su et al., 2021; 33766983), and colorectal cancer (CRC), especially in KRAS_mutant CRC (Deb et al., 2014; 24548858). There are no therapies to target alterations in this gene.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "02", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "02"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Studies of salivary gland carcinomas reported a median tumor mutational burden (TMB) of 1.7_3.6 Muts/Mb for salivary gland carcinomas, with 13% of salivary gland carcinoma cases harboring a TMB of \u226510 Muts/Mb (FMI_Chalmers et al., 2017; 28420421, Shao et al., 2020; 33119110). For patients with salivary gland carcinoma not treated with immunotherapy, no significant association between high levels of tissue tumor mutational burden (TMB) (\u226510 mut/Mb) and OS was reported in one study, although OS numerically differed between patients with high and lower TMB (4.5 vs. 15.5 months, adjusted HR=1.20) (Shao et al., 2020; 33119110). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "HRAS", "Alteration": "Q61R", "Title": "DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BRAF, MEK", "Locations": "Busan (Korea, Republic of), Seoul (Korea, Republic of), Oregon, Barcelona (Spain), Madrid (Spain), California, Colorado, Toronto (Canada), Indiana", "NCTID": "NCT04985604", "Note": "HRAS activating alterations may predict sensitivity to MEK or farnesyl transferase inhibitors.", "Include": "true"}, {"Gene": "HRAS", "Alteration": "Q61R", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "HRAS activating alterations may predict sensitivity to MEK or farnesyl transferase inhibitors.", "Include": "true"}, {"Gene": "HRAS", "Alteration": "Q61R", "Title": "Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, RAFs, NRAS", "Locations": "Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of)", "NCTID": "NCT03284502", "Note": "HRAS activating alterations may predict sensitivity to MEK or farnesyl transferase inhibitors.", "Include": "true"}, {"Gene": "HRAS", "Alteration": "Q61R", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "HRAS activating alterations may predict sensitivity to MEK or farnesyl transferase inhibitors.", "Include": "true"}, {"Gene": "HRAS", "Alteration": "Q61R", "Title": "JAB_3312 Activity in Adult Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "MEK, SHP2, PD_1, EGFR, KRAS", "Locations": "Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut", "NCTID": "NCT04720976", "Note": "HRAS activating alterations may predict sensitivity to MEK or farnesyl transferase inhibitors.", "Include": "true"}, {"Gene": "HRAS", "Alteration": "Q61R", "Title": "Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer", "StudyPhase": "PHASE 1/2", "Target": "MEK, FGFRs", "Locations": "California, Indiana, Texas", "NCTID": "NCT04965818", "Note": "HRAS activating alterations may predict sensitivity to MEK or farnesyl transferase inhibitors.", "Include": "true"}, {"Gene": "HRAS", "Alteration": "Q61R", "Title": "Study of the Safety and Pharmacokinetics of BGB_283 and PD_0325901 in Patients With Advanced or Refractory Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "RAFs, EGFR, MEK", "Locations": "Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), California, Texas", "NCTID": "NCT03905148", "Note": "HRAS activating alterations may predict sensitivity to MEK or farnesyl transferase inhibitors.", "Include": "true"}, {"Gene": "HRAS", "Alteration": "Q61R", "Title": "The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs", "StudyPhase": "PHASE 2", "Target": "BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6", "Locations": "Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)", "NCTID": "NCT05159245", "Note": "HRAS activating alterations may predict sensitivity to MEK or farnesyl transferase inhibitors.", "Include": "true"}, {"Gene": "HRAS", "Alteration": "Q61R", "Title": "CRAFT: The NCT_PMO_1602 Phase II Trial", "StudyPhase": "PHASE 2", "Target": "PD_L1, AKTs, MEK, BRAF, ALK, RET, ERBB2", "Locations": "W\u00fcrzburg (Germany), Mainz (Germany), Heidelberg (Germany), T\u00fcbingen (Germany)", "NCTID": "NCT04551521", "Note": "HRAS activating alterations may predict sensitivity to MEK or farnesyl transferase inhibitors.", "Include": "true"}, {"Gene": "HRAS", "Alteration": "Q61R", "Title": "A Safety, Tolerability and PK Study of DCC_3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.", "StudyPhase": "PHASE 1/2", "Target": "ULK1, ULK2, MEK", "Locations": "Massachusetts, Texas, Pennsylvania", "NCTID": "NCT04892017", "Note": "HRAS activating alterations may predict sensitivity to MEK or farnesyl transferase inhibitors.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma", "StudyPhase": "PHASE 1/2", "Target": "CDK2, CDK9", "Locations": "Seoul (Korea, Republic of), Barcelona (Spain), California, Texas", "NCTID": "NCT04983810", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "NUV_868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BRD4, PARP, AR", "Locations": "Michigan, Texas, Tennessee, Maryland, Virginia, North Carolina", "NCTID": "NCT05252390", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Crossover Relative Bioavailability and Dose Escalation Study of TT_00420 Tablet in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "Aurora kinase A, Aurora kinase B", "Locations": "California, Illinois, Ohio, Texas, New Jersey", "NCTID": "NCT04742959", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_1, CTLA_4, BRD4, BRDT, BRD2, BRD3", "Locations": "Ohio, Pennsylvania, New York, Maryland", "NCTID": "NCT04840589", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Alisertib and Pembrolizumab for the Treatment of Patients With Rb_deficient Head and Neck Squamous Cell Cancer", "StudyPhase": "PHASE 1/2", "Target": "Aurora kinase A, PD_1", "Locations": "Texas", "NCTID": "NCT04555837", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PARP, CDK1, CDK9, CDK5, CDK2", "Locations": "Massachusetts", "NCTID": "NCT01434316", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K, P539R", "Title": "Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha, RAFs, NRAS", "Locations": "Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Shanghai City (China), Shanghai (China), Shatin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi an (China), Tianjin (China)", "NCTID": "NCT04589845", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K, P539R", "Title": "A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.", "StudyPhase": "PHASE 1", "Target": "AKTs", "Locations": "Shanghai City (China)", "NCTID": "NCT04341259", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K, P539R", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K, P539R", "Title": "Alpelisib and Paclitaxel in PIK3CA_altered Gastric Cancer", "StudyPhase": "PHASE 1/2", "Target": "PI3K_alpha", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of)", "NCTID": "NCT04526470", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K, P539R", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K, P539R", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K, P539R", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K, P539R", "Title": "CRAFT: The NCT_PMO_1602 Phase II Trial", "StudyPhase": "PHASE 2", "Target": "PD_L1, AKTs, MEK, BRAF, ALK, RET, ERBB2", "Locations": "W\u00fcrzburg (Germany), Mainz (Germany), Heidelberg (Germany), T\u00fcbingen (Germany)", "NCTID": "NCT04551521", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K, P539R", "Title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR", "Locations": "Washington, Oregon, Idaho, Montana", "NCTID": "NCT03994796", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E545K, P539R", "Title": "To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC_0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer", "StudyPhase": "PHASE 1", "Target": "PI3K_alpha, Aromatase, ER, CDK6, CDK4", "Locations": "London (United Kingdom), Surrey (United Kingdom), Bordeaux (France), Barcelona (Spain), Valencia (Spain), Toronto (Canada), Massachusetts, New York, Tennessee", "NCTID": "NCT03006172", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "16904903", "FullCitation": "Dang CV, et al. Semin. Cancer Biol. (2006) pmid: 16904903", "Include": "true"}, {"number": "1", "ReferenceId": "10378696", "FullCitation": "Nesbit CE, et al. Oncogene (1999) pmid: 10378696", "Include": "true"}, {"number": "2", "ReferenceId": "15083194", "FullCitation": "Blancato J, et al. Br. J. Cancer (2004) pmid: 15083194", "Include": "true"}, {"number": "3", "ReferenceId": "23574779", "FullCitation": "Fromont G, et al. Hum. Pathol. (2013) pmid: 23574779", "Include": "true"}, {"number": "4", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "5", "ReferenceId": "8396843", "FullCitation": "Deguchi H, et al. Acta Pathol. Jpn. () pmid: 8396843", "Include": "true"}, {"number": "6", "ReferenceId": "23725736", "FullCitation": "von Holstein SL, et al. Ophthalmology (2013) pmid: 23725736", "Include": "true"}, {"number": "7", "ReferenceId": "28594149", "FullCitation": "Fujii K, et al. Histopathology (2017) pmid: 28594149", "Include": "true"}, {"number": "8", "ReferenceId": "22430491", "FullCitation": "Horiuchi D, et al. J. Exp. Med. (2012) pmid: 22430491", "Include": "true"}, {"number": "9", "ReferenceId": "17589519", "FullCitation": "Goga A, et al. Nat. Med. (2007) pmid: 17589519", "Include": "true"}, {"number": "10", "ReferenceId": "19525400", "FullCitation": "Molenaar JJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19525400", "Include": "true"}, {"number": "11", "ReferenceId": "31375684", "FullCitation": "Dammert MA, et al. Nat Commun (2019) pmid: 31375684", "Include": "true"}, {"number": "12", "ReferenceId": "28089889", "FullCitation": "Mollaoglu G, et al. Cancer Cell (2017) pmid: 28089889", "Include": "true"}, {"number": "13", "ReferenceId": "29088717", "FullCitation": "Cardnell RJ, et al. Oncotarget (2017) pmid: 29088717", "Include": "true"}, {"number": "14", "ReferenceId": "28417568", "FullCitation": "Wang L, et al. Mol Oncol (2017) pmid: 28417568", "Include": "true"}, {"number": "15", "ReferenceId": "25632068", "FullCitation": "Takahashi Y, et al. Ann. Oncol. (2015) pmid: 25632068", "Include": "true"}, {"number": "16", "ReferenceId": "30226440", "FullCitation": "Li Y, et al. Thyroid (2018) pmid: 30226440", "Include": "true"}, {"number": "17", "ReferenceId": "24893165", "FullCitation": "Mahadevan D, et al. PLoS ONE (2014) pmid: 24893165", "Include": "true"}, {"number": "18", "ReferenceId": "31429028", "FullCitation": "Park SI, et al. Target Oncol (2019) pmid: 31429028", "Include": "true"}, {"number": "19", "ReferenceId": "27496133", "FullCitation": "Helfrich BA, et al. Mol. Cancer Ther. (2016) pmid: 27496133", "Include": "true"}, {"number": "20", "ReferenceId": "22222631", "FullCitation": "Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631", "Include": "true"}, {"number": "21", "ReferenceId": "20643922", "FullCitation": "Yang D, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20643922", "Include": "true"}, {"number": "22", "ReferenceId": "30540594", "FullCitation": "He J, et al. Anticancer Drugs (2019) pmid: 30540594", "Include": "true"}, {"number": "23", "ReferenceId": "25964345", "FullCitation": "Shroff EH, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25964345", "Include": "true"}, {"number": "24", "ReferenceId": "29156762", "FullCitation": "Effenberger M, et al. Oncotarget (2017) pmid: 29156762", "Include": "true"}, {"number": "25", "ReferenceId": "30103944", "FullCitation": "Qu X, et al. Biochem. Biophys. Res. Commun. (2018) pmid: 30103944", "Include": "true"}, {"number": "26", "ReferenceId": "25915584", "FullCitation": "Xiang Y, et al. J. Clin. Invest. (2015) pmid: 25915584", "Include": "true"}, {"number": "27", "ReferenceId": "21889194", "FullCitation": "Delmore JE, et al. Cell (2011) pmid: 21889194", "Include": "true"}, {"number": "28", "ReferenceId": "24297863", "FullCitation": "Bandopadhayay P, et al. Clin. Cancer Res. (2014) pmid: 24297863", "Include": "true"}, {"number": "29", "ReferenceId": "23582323", "FullCitation": "Lov\u00e9n J, et al. Cell (2013) pmid: 23582323", "Include": "true"}, {"number": "30", "ReferenceId": "31734632", "FullCitation": "Otto C, et al. Neoplasia (2019) pmid: 31734632", "Include": "true"}, {"number": "31", "ReferenceId": "23866964", "FullCitation": "Dong LH, et al. J Hematol Oncol (2013) pmid: 23866964", "Include": "true"}, {"number": "32", "ReferenceId": "26977882", "FullCitation": "Pei Y, et al. Cancer Cell (2016) pmid: 26977882", "Include": "true"}, {"number": "33", "ReferenceId": "30224636", "FullCitation": "Fu XH, et al. Acta Pharmacol. Sin. (2019) pmid: 30224636", "Include": "true"}, {"number": "34", "ReferenceId": "31655296", "FullCitation": "Owonikoko TK, et al. J Thorac Oncol (2020) pmid: 31655296", "Include": "true"}, {"number": "35", "ReferenceId": "25253784", "FullCitation": "Ganesan P, et al. Mol. Cancer Ther. (2014) pmid: 25253784", "Include": "true"}, {"number": "36", "ReferenceId": "23555992", "FullCitation": "Pereira CB, et al. PLoS ONE (2013) pmid: 23555992", "Include": "true"}, {"number": "37", "ReferenceId": "21741827", "FullCitation": "Yasojima H, et al. Eur. J. Cancer (2011) pmid: 21741827", "Include": "true"}, {"number": "38", "ReferenceId": "11406570", "FullCitation": "Arango D, et al. Cancer Res. (2001) pmid: 11406570", "Include": "true"}, {"number": "39", "ReferenceId": "14516787", "FullCitation": "Bottone MG, et al. Exp. Cell Res. (2003) pmid: 14516787", "Include": "true"}, {"number": "40", "ReferenceId": "15950905", "FullCitation": "Samuels Y, et al. Cancer Cell (2005) pmid: 15950905", "Include": "true"}, {"number": "41", "ReferenceId": "19629070", "FullCitation": "Nat. Rev. Cancer (2009) pmid: 19629070", "Include": "true"}, {"number": "42", "ReferenceId": "15647370", "FullCitation": "Kang S, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15647370", "Include": "true"}, {"number": "43", "ReferenceId": "15930273", "FullCitation": "Ikenoue T, et al. Cancer Res. (2005) pmid: 15930273", "Include": "true"}, {"number": "44", "ReferenceId": "17376864", "FullCitation": "Gymnopoulos M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17376864", "Include": "true"}, {"number": "45", "ReferenceId": "18317450", "FullCitation": "Horn S, et al. Oncogene (2008) pmid: 18317450", "Include": "true"}, {"number": "46", "ReferenceId": "21266528", "FullCitation": "Rudd ML, et al. Clin. Cancer Res. (2011) pmid: 21266528", "Include": "true"}, {"number": "47", "ReferenceId": "22120714", "FullCitation": "Hon WC, et al. Oncogene (2012) pmid: 22120714", "Include": "true"}, {"number": "48", "ReferenceId": "22949682", "FullCitation": "Burke JE, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22949682", "Include": "true"}, {"number": "49", "ReferenceId": "19915146", "FullCitation": "Wu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19915146", "Include": "true"}, {"number": "50", "ReferenceId": "2103068", "FullCitation": "Laurenti R, et al. Rev Saude Publica (1990) pmid: 2103068", "Include": "true"}, {"number": "51", "ReferenceId": "20530683", "FullCitation": "Dan S, et al. Cancer Res. (2010) pmid: 20530683", "Include": "true"}, {"number": "52", "ReferenceId": "18829572", "FullCitation": "Oda K, et al. Cancer Res. (2008) pmid: 18829572", "Include": "true"}, {"number": "53", "ReferenceId": "18794883", "FullCitation": "Zhao L, et al. Oncogene (2008) pmid: 18794883", "Include": "true"}, {"number": "54", "ReferenceId": "23619167", "FullCitation": "Lui VW, et al. Cancer Discov (2013) pmid: 23619167", "Include": "true"}, {"number": "55", "ReferenceId": "22430209", "FullCitation": "Ross RL, et al. Oncogene (2013) pmid: 22430209", "Include": "true"}, {"number": "56", "ReferenceId": "22729224", "FullCitation": "Rivi\u00e8re JB, et al. Nat. Genet. (2012) pmid: 22729224", "Include": "true"}, {"number": "57", "ReferenceId": "19394761", "FullCitation": "Shibata T, et al. Cancer Lett. (2009) pmid: 19394761", "Include": "true"}, {"number": "58", "ReferenceId": "26627007", "FullCitation": "Dogruluk T, et al. Cancer Res. (2015) pmid: 26627007", "Include": "true"}, {"number": "59", "ReferenceId": "29284706", "FullCitation": "Croessmann S, et al. Clin. Cancer Res. (2018) pmid: 29284706", "Include": "true"}, {"number": "60", "ReferenceId": "29533785", "FullCitation": "Ng PK, et al. Cancer Cell (2018) pmid: 29533785", "Include": "true"}, {"number": "61", "ReferenceId": "32929011", "FullCitation": "Spangle JM, et al. (2020) pmid: 32929011", "Include": "true"}, {"number": "62", "ReferenceId": "29636477", "FullCitation": "Chen L, et al. Nat Commun (2018) pmid: 29636477", "Include": "true"}, {"number": "63", "ReferenceId": "34779417", "FullCitation": "Jin N, et al. J Clin Invest (2021) pmid: 34779417", "Include": "true"}, {"number": "64", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "65", "ReferenceId": "22722201", "FullCitation": "Stephens PJ, et al. Nature (2012) pmid: 22722201", "Include": "true"}, {"number": "66", "ReferenceId": "22722202", "FullCitation": "Banerji S, et al. Nature (2012) pmid: 22722202", "Include": "true"}, {"number": "67", "ReferenceId": "23000897", "FullCitation": "Nature (2012) pmid: 23000897", "Include": "true"}, {"number": "68", "ReferenceId": "24476821", "FullCitation": "Nature (2014) pmid: 24476821", "Include": "true"}, {"number": "69", "ReferenceId": "24121792", "FullCitation": "Guo G, et al. Nat. Genet. (2013) pmid: 24121792", "Include": "true"}, {"number": "70", "ReferenceId": "23897969", "FullCitation": "Iyer G, et al. J. Clin. Oncol. (2013) pmid: 23897969", "Include": "true"}, {"number": "71", "ReferenceId": "25092538", "FullCitation": "Kim PH, et al. Eur. Urol. (2015) pmid: 25092538", "Include": "true"}, {"number": "72", "ReferenceId": "25631445", "FullCitation": "Nature (2015) pmid: 25631445", "Include": "true"}, {"number": "73", "ReferenceId": "25079317", "FullCitation": "Nature (2014) pmid: 25079317", "Include": "true"}, {"number": "74", "ReferenceId": "24608574", "FullCitation": "Fritsch C, et al. Mol. Cancer Ther. (2014) pmid: 24608574", "Include": "true"}, {"number": "75", "ReferenceId": "29401002", "FullCitation": "Juric D, et al. J. Clin. Oncol. (2018) pmid: 29401002", "Include": "true"}, {"number": "76", "ReferenceId": "30793038", "FullCitation": "Gallant JN, et al. NPJ Precis Oncol (2019) pmid: 30793038", "Include": "true"}, {"number": "77", "ReferenceId": "34613809", "FullCitation": "Delestre F, et al. Sci Transl Med (2021) pmid: 34613809", "Include": "true"}, {"number": "78", "ReferenceId": "31619463", "FullCitation": "Morschhauser F, et al. Mol Cancer Ther (2020) pmid: 31619463", "Include": "true"}, {"number": "79", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "80", "ReferenceId": "31934607", "FullCitation": "Santin AD, et al. Gynecol Oncol Rep (2020) pmid: 31934607", "Include": "true"}, {"number": "81", "ReferenceId": "35133871", "FullCitation": "Damodaran S, et al. J Clin Oncol (2022) pmid: 35133871", "Include": "true"}, {"number": "82", "ReferenceId": "31091374", "FullCitation": "Andr\u00e9 F, et al. N. Engl. J. Med. (2019) pmid: 31091374", "Include": "true"}, {"number": "83", "ReferenceId": "33863913", "FullCitation": "Smyth LM, et al. NPJ Breast Cancer (2021) pmid: 33863913", "Include": "true"}, {"number": "84", "ReferenceId": "31351267", "FullCitation": "Varnier R, et al. Eur J Cancer (2019) pmid: 31351267", "Include": "true"}, {"number": "85", "ReferenceId": "32914004", "FullCitation": "Basse C, et al. JCO Precis Oncol (2018) pmid: 32914004", "Include": "true"}, {"number": "86", "ReferenceId": "33277683", "FullCitation": "Sultova E, et al. Arch Gynecol Obstet (2021) pmid: 33277683", "Include": "true"}, {"number": "87", "ReferenceId": "24166148", "FullCitation": "Mackay HJ, et al. Cancer (2014) pmid: 24166148", "Include": "true"}, {"number": "88", "ReferenceId": "27016228", "FullCitation": "Myers AP, et al. Gynecol. Oncol. (2016) pmid: 27016228", "Include": "true"}, {"number": "89", "ReferenceId": "29588307", "FullCitation": "Dhami J, et al. Cold Spring Harb Mol Case Stud (2018) pmid: 29588307", "Include": "true"}, {"number": "90", "ReferenceId": "30863722", "FullCitation": "Harris EJ, et al. Front Oncol (2019) pmid: 30863722", "Include": "true"}, {"number": "91", "ReferenceId": "29301825", "FullCitation": "Hanna GJ, et al. Clin Cancer Res (2018) pmid: 29301825", "Include": "true"}, {"number": "92", "ReferenceId": "32958578", "FullCitation": "Pascual J, et al. Cancer Discov (2021) pmid: 32958578", "Include": "true"}, {"number": "93", "ReferenceId": "26787751", "FullCitation": "Dolly SO, et al. Clin. Cancer Res. (2016) pmid: 26787751", "Include": "true"}, {"number": "94", "ReferenceId": "2941002", "FullCitation": "Aust Fam Physician (1986) pmid: 2941002", "Include": "true"}, {"number": "95", "ReferenceId": "21993244", "FullCitation": "Pylayeva_Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244", "Include": "true"}, {"number": "96", "ReferenceId": "24247240", "FullCitation": "Baker R, et al. J. Biol. Chem. (2013) pmid: 24247240", "Include": "true"}, {"number": "97", "ReferenceId": "20194776", "FullCitation": "Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776", "Include": "true"}, {"number": "98", "ReferenceId": "17979197", "FullCitation": "Denayer E, et al. Hum. Mutat. (2008) pmid: 17979197", "Include": "true"}, {"number": "99", "ReferenceId": "6330729", "FullCitation": "Fasano O, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6330729", "Include": "true"}, {"number": "100", "ReferenceId": "3043178", "FullCitation": "Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178", "Include": "true"}, {"number": "101", "ReferenceId": "20570890", "FullCitation": "Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890", "Include": "true"}, {"number": "102", "ReferenceId": "1565661", "FullCitation": "Priv\u00e9 GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661", "Include": "true"}, {"number": "103", "ReferenceId": "9219684", "FullCitation": "Scheffzek K, et al. Science (1997) pmid: 9219684", "Include": "true"}, {"number": "104", "ReferenceId": "24651010", "FullCitation": "Stephen AG, et al. Cancer Cell (2014) pmid: 24651010", "Include": "true"}, {"number": "105", "ReferenceId": "21850009", "FullCitation": "Niihori T, et al. J. Hum. Genet. (2011) pmid: 21850009", "Include": "true"}, {"number": "106", "ReferenceId": "24224811", "FullCitation": "Wey M, et al. Biochemistry (2013) pmid: 24224811", "Include": "true"}, {"number": "107", "ReferenceId": "31160609", "FullCitation": "Eijkelenboom A, et al. Sci Rep (2019) pmid: 31160609", "Include": "true"}, {"number": "108", "ReferenceId": "23335589", "FullCitation": "Lorenz S, et al. Hum Mol Genet (2013) pmid: 23335589", "Include": "true"}, {"number": "109", "ReferenceId": "19317835", "FullCitation": "Oral Dis (2009) pmid: 19317835", "Include": "true"}, {"number": "110", "ReferenceId": "21618326", "FullCitation": "Vander Poorten V, et al. Head Neck (2012) pmid: 21618326", "Include": "true"}, {"number": "111", "ReferenceId": "8106812", "FullCitation": "Milasin J, et al. Int J Oral Maxillofac Surg (1993) pmid: 8106812", "Include": "true"}, {"number": "112", "ReferenceId": "8168996", "FullCitation": "van Halteren HK, et al. Int. J. Cancer (1994) pmid: 8168996", "Include": "true"}, {"number": "113", "ReferenceId": "10649241", "FullCitation": "Yoo J, et al. Cancer (2000) pmid: 10649241", "Include": "true"}, {"number": "114", "ReferenceId": "10835516", "FullCitation": "Yoo J, et al. Arch. Pathol. Lab. Med. (2000) pmid: 10835516", "Include": "true"}, {"number": "115", "ReferenceId": "23933559", "FullCitation": "Cros J, et al. Ann. Oncol. (2013) pmid: 23933559", "Include": "true"}, {"number": "116", "ReferenceId": "19035362", "FullCitation": "Rosenberger G, et al. Hum. Mutat. (2009) pmid: 19035362", "Include": "true"}, {"number": "117", "ReferenceId": "18163378", "FullCitation": "Rosseland CM, et al. J. Cell. Physiol. (2008) pmid: 18163378", "Include": "true"}, {"number": "118", "ReferenceId": "22399013", "FullCitation": "Ricciardi MR, et al. J. Mol. Med. (2012) pmid: 22399013", "Include": "true"}, {"number": "119", "ReferenceId": "25933688", "FullCitation": "Leiser D, et al. Mol Oncol (2015) pmid: 25933688", "Include": "true"}, {"number": "120", "ReferenceId": "26544513", "FullCitation": "Kiessling MK, et al. Oncotarget (2015) pmid: 26544513", "Include": "true"}, {"number": "121", "ReferenceId": "9628872", "FullCitation": "Strong JE, et al. EMBO J. (1998) pmid: 9628872", "Include": "true"}, {"number": "122", "ReferenceId": "9812900", "FullCitation": "Coffey MC, et al. Science (1998) pmid: 9812900", "Include": "true"}, {"number": "123", "ReferenceId": "25019061", "FullCitation": "Gong J, et al. Front Oncol (2014) pmid: 25019061", "Include": "true"}, {"number": "124", "ReferenceId": "18253152", "FullCitation": "Forsyth P, et al. Mol. Ther. (2008) pmid: 18253152", "Include": "true"}, {"number": "125", "ReferenceId": "18981012", "FullCitation": "Vidal L, et al. Clin. Cancer Res. (2008) pmid: 18981012", "Include": "true"}, {"number": "126", "ReferenceId": "19572105", "FullCitation": "Gollamudi R, et al. Invest New Drugs (2010) pmid: 19572105", "Include": "true"}, {"number": "127", "ReferenceId": "20484020", "FullCitation": "Harrington KJ, et al. Clin. Cancer Res. (2010) pmid: 20484020", "Include": "true"}, {"number": "128", "ReferenceId": "20926400", "FullCitation": "Comins C, et al. Clin. Cancer Res. (2010) pmid: 20926400", "Include": "true"}, {"number": "129", "ReferenceId": "21106728", "FullCitation": "Lolkema MP, et al. Clin. Cancer Res. (2011) pmid: 21106728", "Include": "true"}, {"number": "130", "ReferenceId": "22871663", "FullCitation": "Galanis E, et al. Mol. Ther. (2012) pmid: 22871663", "Include": "true"}, {"number": "131", "ReferenceId": "22316603", "FullCitation": "Karapanagiotou EM, et al. Clin. Cancer Res. (2012) pmid: 22316603", "Include": "true"}, {"number": "132", "ReferenceId": "22886613", "FullCitation": "Morris DG, et al. Invest New Drugs (2013) pmid: 22886613", "Include": "true"}, {"number": "133", "ReferenceId": "11196150", "FullCitation": "End DW, et al. Cancer Res. (2001) pmid: 11196150", "Include": "true"}, {"number": "134", "ReferenceId": "24240680", "FullCitation": "Chen X, et al. Oncogene (2014) pmid: 24240680", "Include": "true"}, {"number": "135", "ReferenceId": "10931682", "FullCitation": "Cohen_Jonathan E, et al. Radiat. Res. (2000) pmid: 10931682", "Include": "true"}, {"number": "136", "ReferenceId": "22067401", "FullCitation": "Oberholzer PA, et al. J. Clin. Oncol. (2012) pmid: 22067401", "Include": "true"}, {"number": "137", "ReferenceId": "22256804", "FullCitation": "Su F, et al. N. Engl. J. Med. (2012) pmid: 22256804", "Include": "true"}, {"number": "138", "ReferenceId": "23457002", "FullCitation": "Lacouture ME, et al. Oncologist (2013) pmid: 23457002", "Include": "true"}, {"number": "139", "ReferenceId": "24123531", "FullCitation": "Hah JH, et al. Head Neck (2014) pmid: 24123531", "Include": "true"}, {"number": "140", "ReferenceId": "23559083", "FullCitation": "Frasca F, et al. J. Clin. Endocrinol. Metab. (2013) pmid: 23559083", "Include": "true"}, {"number": "141", "ReferenceId": "22797062", "FullCitation": "Kasper S, et al. Oncogene (2013) pmid: 22797062", "Include": "true"}, {"number": "142", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "143", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "144", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "145", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "146", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "147", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "148", "ReferenceId": "9917133", "FullCitation": "Suzuki H, et al. Diagn. Mol. Pathol. (1998) pmid: 9917133", "Include": "true"}, {"number": "149", "ReferenceId": "31762146", "FullCitation": "Moore A, et al. Head Neck (2020) pmid: 31762146", "Include": "true"}, {"number": "150", "ReferenceId": "11829237", "FullCitation": "Ohki K, et al. Int J Oral Maxillofac Surg (2001) pmid: 11829237", "Include": "true"}, {"number": "151", "ReferenceId": "30846173", "FullCitation": "Nakano T, et al. Oral Oncol. (2019) pmid: 30846173", "Include": "true"}, {"number": "152", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "153", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "154", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "155", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "156", "ReferenceId": "21326324", "FullCitation": "Xu H, et al. Nat. Rev. Cancer (2011) pmid: 21326324", "Include": "true"}, {"number": "157", "ReferenceId": "27207471", "FullCitation": "Hill VK, et al. Biochim. Biophys. Acta (2016) pmid: 27207471", "Include": "true"}, {"number": "158", "ReferenceId": "24856830", "FullCitation": "Solomon DA, et al. BMB Rep (2014) pmid: 24856830", "Include": "true"}, {"number": "159", "ReferenceId": "19906707", "FullCitation": "Bauerschmidt C, et al. Nucleic Acids Res. (2010) pmid: 19906707", "Include": "true"}, {"number": "160", "ReferenceId": "26420833", "FullCitation": "Yun J, et al. Nucleic Acids Res. (2016) pmid: 26420833", "Include": "true"}, {"number": "161", "ReferenceId": "27326661", "FullCitation": "Gelot C, et al. Nucleus (2016) pmid: 27326661", "Include": "true"}, {"number": "162", "ReferenceId": "22537934", "FullCitation": "Yan M, et al. Breast Cancer Res. (2012) pmid: 22537934", "Include": "true"}, {"number": "163", "ReferenceId": "24185899", "FullCitation": "Sofueva S, et al. EMBO J. (2013) pmid: 24185899", "Include": "true"}, {"number": "164", "ReferenceId": "23010778", "FullCitation": "Deng Z, et al. EMBO J. (2012) pmid: 23010778", "Include": "true"}, {"number": "165", "ReferenceId": "27466323", "FullCitation": "Yun J, et al. EMBO Rep. (2016) pmid: 27466323", "Include": "true"}, {"number": "166", "ReferenceId": "21255398", "FullCitation": "Xu H, et al. Breast Cancer Res. (2011) pmid: 21255398", "Include": "true"}, {"number": "167", "ReferenceId": "24148822", "FullCitation": "Mahmood SF, et al. Carcinogenesis (2014) pmid: 24148822", "Include": "true"}, {"number": "168", "ReferenceId": "23205091", "FullCitation": "Supernat A, et al. Oncol Lett (2012) pmid: 23205091", "Include": "true"}, {"number": "169", "ReferenceId": "35227290", "FullCitation": "Sharaf R, et al. Genome Med (2022) pmid: 35227290", "Include": "true"}, {"number": "170", "ReferenceId": "33766983", "FullCitation": "Su XA, et al. Genes Dev (2021) pmid: 33766983", "Include": "true"}, {"number": "171", "ReferenceId": "24548858", "FullCitation": "Deb S, et al. Br. J. Cancer (2014) pmid: 24548858", "Include": "true"}, {"number": "172", "ReferenceId": "15664155", "FullCitation": "Xu Y, et al. Immunity (2005) pmid: 15664155", "Include": "true"}, {"number": "173", "ReferenceId": "22805580", "FullCitation": "Cell Commun. Signal (2012) pmid: 22805580", "Include": "true"}, {"number": "174", "ReferenceId": "35120664", "FullCitation": "Nguyen B, et al. Cell (2022) pmid: 35120664", "Include": "true"}, {"number": "175", "ReferenceId": "15994925", "FullCitation": "Stettner MR, et al. Cancer Res. (2005) pmid: 15994925", "Include": "true"}, {"number": "176", "ReferenceId": "14871838", "FullCitation": "Goldenberg_Furmanov M, et al. Cancer Res. (2004) pmid: 14871838", "Include": "true"}, {"number": "177", "ReferenceId": "22490227", "FullCitation": "Wheeler SE, et al. Clin. Cancer Res. (2012) pmid: 22490227", "Include": "true"}, {"number": "178", "ReferenceId": "18644993", "FullCitation": "Guan H, et al. Mol. Cancer Ther. (2008) pmid: 18644993", "Include": "true"}, {"number": "179", "ReferenceId": "20215510", "FullCitation": "Choi YL, et al. Cancer Res. (2010) pmid: 20215510", "Include": "true"}, {"number": "180", "ReferenceId": "23764002", "FullCitation": "Huang TH, et al. Cancer Cell (2013) pmid: 23764002", "Include": "true"}, {"number": "181", "ReferenceId": "26984511", "FullCitation": "Roseweir AK, et al. BMC Cancer (2016) pmid: 26984511", "Include": "true"}, {"number": "182", "ReferenceId": "16230377", "FullCitation": "Nam S, et al. Cancer Res. (2005) pmid: 16230377", "Include": "true"}, {"number": "183", "ReferenceId": "18984583", "FullCitation": "Williams NK, et al. J. Biol. Chem. (2009) pmid: 18984583", "Include": "true"}, {"number": "184", "ReferenceId": "32266142", "FullCitation": "Dai HP, et al. Front Oncol (2020) pmid: 32266142", "Include": "true"}, {"number": "185", "ReferenceId": "33199837", "FullCitation": "Tomii T, et al. Leukemia (2021) pmid: 33199837", "Include": "true"}, {"number": "186", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "187", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "188", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "189", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "190", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "191", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "192", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "193", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "194", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "195", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "196", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "197", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "198", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "199", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "200", "ReferenceId": "33119110", "FullCitation": "Shao C, et al. JAMA Netw Open (2020) pmid: 33119110", "Include": "true"}, {"number": "201", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "202", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "203", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "204", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "205", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "206", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "207", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "208", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "209", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "210", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "211", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "212", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "213", "ReferenceId": "25344362", "FullCitation": "Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362", "Include": "true"}, {"number": "214", "ReferenceId": "23583440", "FullCitation": "Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440", "Include": "true"}, {"number": "215", "ReferenceId": "22805291", "FullCitation": "Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291", "Include": "true"}, {"number": "216", "ReferenceId": "22767668", "FullCitation": "Leijen S, et al. Clin. Cancer Res. (2012) pmid: 22767668", "Include": "true"}, {"number": "217", "ReferenceId": "24947927", "FullCitation": "Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927", "Include": "true"}, {"number": "218", "ReferenceId": "26566875", "FullCitation": "Diamond EL, et al. Cancer Discov (2016) pmid: 26566875", "Include": "true"}, {"number": "219", "ReferenceId": "30867592", "FullCitation": "Diamond EL, et al. Nature (2019) pmid: 30867592", "Include": "true"}, {"number": "220", "ReferenceId": "29236635", "FullCitation": "Jacobsen E, et al. N. Engl. J. Med. (2017) pmid: 29236635", "Include": "true"}, {"number": "221", "ReferenceId": "35372654", "FullCitation": "Berce PC, et al. JAAD Case Rep (2022) pmid: 35372654", "Include": "true"}, {"number": "222", "ReferenceId": "32823478", "FullCitation": "Giuffr\u00e8 C, et al. Indian J Ophthalmol (2020) pmid: 32823478", "Include": "true"}, {"number": "223", "ReferenceId": "31376269", "FullCitation": "Razanamahery J, et al. Clin Exp Rheumatol () pmid: 31376269", "Include": "true"}, {"number": "224", "ReferenceId": "31669429", "FullCitation": "Moyon Q, et al. Chest (2020) pmid: 31669429", "Include": "true"}, {"number": "225", "ReferenceId": "36135991", "FullCitation": "Gupta RK, et al. Neurol Int (2022) pmid: 36135991", "Include": "true"}, {"number": "226", "ReferenceId": "27424159", "FullCitation": "Rosen LS, et al. Invest New Drugs (2016) pmid: 27424159", "Include": "true"}, {"number": "227", "ReferenceId": "33903938", "FullCitation": "Schalkwijk S, et al. Cancer Chemother Pharmacol (2021) pmid: 33903938", "Include": "true"}, {"number": "228", "ReferenceId": "28029918", "FullCitation": "Dombi E, et al. N. Engl. J. Med. (2016) pmid: 28029918", "Include": "true"}, {"number": "229", "ReferenceId": "31151904", "FullCitation": "Fangusaro J, et al. Lancet Oncol. (2019) pmid: 31151904", "Include": "true"}, {"number": "230", "ReferenceId": "28339824", "FullCitation": "Banerjee A, et al. Neuro_oncology (2017) pmid: 28339824", "Include": "true"}, {"number": "231", "ReferenceId": "24567366", "FullCitation": "Gupta A, et al. Ann. Oncol. (2014) pmid: 24567366", "Include": "true"}, {"number": "232", "ReferenceId": "23735514", "FullCitation": "Robert C, et al. Lancet Oncol. (2013) pmid: 23735514", "Include": "true"}, {"number": "233", "ReferenceId": "22048237", "FullCitation": "Kirkwood JM, et al. Clin. Cancer Res. (2012) pmid: 22048237", "Include": "true"}, {"number": "234", "ReferenceId": "20179232", "FullCitation": "Banerji U, et al. Clin. Cancer Res. (2010) pmid: 20179232", "Include": "true"}, {"number": "235", "ReferenceId": "22293660", "FullCitation": "Boers_Sonderen MJ, et al. Anticancer Drugs (2012) pmid: 22293660", "Include": "true"}, {"number": "236", "ReferenceId": "25667274", "FullCitation": "Lopez_Chavez A, et al. J. Clin. Oncol. (2015) pmid: 25667274", "Include": "true"}, {"number": "237", "ReferenceId": "20802351", "FullCitation": "Hainsworth JD, et al. J Thorac Oncol (2010) pmid: 20802351", "Include": "true"}, {"number": "238", "ReferenceId": "32669708", "FullCitation": "Middleton G, et al. Nature (2020) pmid: 32669708", "Include": "true"}, {"number": "239", "ReferenceId": "25887099", "FullCitation": "Coleman RL, et al. Gynecol. Oncol. (2015) pmid: 25887099", "Include": "true"}, {"number": "240", "ReferenceId": "35363510", "FullCitation": "Eckstein OS, et al. J Clin Oncol (2022) pmid: 35363510", "Include": "true"}, {"number": "241", "ReferenceId": "26666244", "FullCitation": "Deming DA, et al. Invest New Drugs (2016) pmid: 26666244", "Include": "true"}, {"number": "242", "ReferenceId": "30042150", "FullCitation": "Krishnamurthy A, et al. Cancer Res. (2018) pmid: 30042150", "Include": "true"}, {"number": "243", "ReferenceId": "28424891", "FullCitation": "Infante JR, et al. Invest New Drugs (2017) pmid: 28424891", "Include": "true"}, {"number": "244", "ReferenceId": "28264648", "FullCitation": "LoRusso PM, et al. BMC Cancer (2017) pmid: 28264648", "Include": "true"}, {"number": "245", "ReferenceId": "25516890", "FullCitation": "Tolcher AW, et al. Clin. Cancer Res. (2015) pmid: 25516890", "Include": "true"}, {"number": "246", "ReferenceId": "25268371", "FullCitation": "Wilky BA, et al. Br. J. Cancer (2015) pmid: 25268371", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_11_28 22:22:16", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "465x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "2 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "SALIVARY GLAND", "disease_ontology": "Salivary gland duct carcinoma", "flowcell_analysis": "2000024929", "gender": "male", "pathology_diagnosis": "Salivary duct carcinoma", "percent_tumor_nuclei": "30", "pipeline_version": "v3.15.0", "purity_assessment": "20.0", "specimen": "ORD_1506062_01*US1441945.02", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1506062_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Lung", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "464.92", "name": "SQ_US1441945.02_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.125", "cds_effect": "182A>G", "depth": "360", "equivocal": "false", "functional_effect": "missense", "gene": "HRAS", "percent_reads": "12.5", "position": "chr11:533874", "protein_effect": "Q61R", "status": "known", "strand": "_", "transcript": "NM_005343", "dna_evidence": {"sample": "SQ_US1441945.02_1"}}, {"allele_fraction": "0.127", "cds_effect": "1616C>G", "depth": "512", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CA", "percent_reads": "12.7", "position": "chr3:178936074", "protein_effect": "P539R", "status": "known", "strand": "+", "transcript": "NM_006218", "dna_evidence": {"sample": "SQ_US1441945.02_1"}}, {"allele_fraction": "0.4735", "cds_effect": "1036C>T", "depth": "471", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA1", "percent_reads": "47.35", "position": "chr17:41246512", "protein_effect": "P346S", "status": "unknown", "strand": "_", "transcript": "NM_007294", "dna_evidence": {"sample": "SQ_US1441945.02_1"}}, {"allele_fraction": "0.4863", "cds_effect": "584G>T", "depth": "547", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK2", "percent_reads": "48.63", "position": "chr9:87338488", "protein_effect": "G195V", "status": "unknown", "strand": "+", "transcript": "NM_006180", "dna_evidence": {"sample": "SQ_US1441945.02_1"}}, {"allele_fraction": "0.5668", "cds_effect": "138G>C", "depth": "591", "equivocal": "false", "functional_effect": "missense", "gene": "CASP8", "percent_reads": "56.68", "position": "chr2:202131347", "protein_effect": "Q46H", "status": "unknown", "strand": "+", "transcript": "NM_001228", "dna_evidence": {"sample": "SQ_US1441945.02_1"}}, {"allele_fraction": "0.3893", "cds_effect": "531_545delAGCAGCCGCGGCGGC", "depth": "244", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "GATA6", "percent_reads": "38.93", "position": "chr18:19751635", "protein_effect": "A179_A183del", "status": "unknown", "strand": "+", "transcript": "NM_005257", "dna_evidence": {"sample": "SQ_US1441945.02_1"}}, {"allele_fraction": "0.4509", "cds_effect": "61C>G", "depth": "448", "equivocal": "false", "functional_effect": "missense", "gene": "CDH1", "percent_reads": "45.09", "position": "chr16:68772212", "protein_effect": "L21V", "status": "unknown", "strand": "+", "transcript": "NM_004360", "dna_evidence": {"sample": "SQ_US1441945.02_1"}}, {"allele_fraction": "0.0789", "cds_effect": "5071A>T", "depth": "380", "equivocal": "false", "functional_effect": "missense", "gene": "CREBBP", "percent_reads": "7.89", "position": "chr16:3781294", "protein_effect": "M1691L", "status": "unknown", "strand": "_", "transcript": "NM_004380", "dna_evidence": {"sample": "SQ_US1441945.02_1"}}, {"allele_fraction": "0.1241", "cds_effect": "1633G>A", "depth": "588", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CA", "percent_reads": "12.41", "position": "chr3:178936091", "protein_effect": "E545K", "status": "known", "strand": "+", "transcript": "NM_006218", "dna_evidence": {"sample": "SQ_US1441945.02_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "9", "equivocal": "false", "gene": "MYC", "number_of_exons": "5 of 5", "position": "chr8:128748789_128753204", "ratio": "1.54", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1441945.02_1"}}, {"copy_number": "9", "equivocal": "false", "gene": "NBN", "number_of_exons": "16 of 16", "position": "chr8:90947760_90996835", "ratio": "1.62", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1441945.02_1"}}, {"copy_number": "9", "equivocal": "false", "gene": "LYN", "number_of_exons": "12 of 12", "position": "chr8:56854418_56922669", "ratio": "1.59", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1441945.02_1"}}, {"copy_number": "9", "equivocal": "false", "gene": "RAD21", "number_of_exons": "13 of 13", "position": "chr8:117859738_117878968", "ratio": "1.77", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1441945.02_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "2.41", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}